TrialJournal of the European Academy of Dermatology and Venereology : JEADV2022

Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis.

J P Thyssen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.